Saudi guidelines on diagnosis and treatment of pulmonary arterial hypertension

[1]  T. Welte,et al.  Experience with inhaled iloprost and bosentan in portopulmonary hypertension , 2007, European Respiratory Journal.

[2]  M. Rubens,et al.  Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. , 2007, Journal of the American College of Cardiology.

[3]  S. Archer,et al.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.

[4]  C. Mullins,et al.  Atrial septostomy improves survival in select patients with pulmonary hypertension. , 2007, American heart journal.

[5]  K. Kerr,et al.  Chronic thromboembolic pulmonary hypertension. , 2001, Clinics in chest medicine.

[6]  R. Benza,et al.  Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  Z. Jing,et al.  Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. , 2006, Journal of the American College of Cardiology.

[8]  W. Seeger,et al.  Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.

[9]  H. Ghofrani,et al.  NO CLINICALLY RELEVANT PHARMACOKINETIC INTERACTION BETWEEN AMBRISENTAN AND SILDENAFIL , 2006 .

[10]  D. Badesch,et al.  ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION , 2006 .

[11]  H. Ghofrani,et al.  AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN , 2006 .

[12]  N. Kim.  Assessment of operability in chronic thromboembolic pulmonary hypertension. , 2006, Proceedings of the American Thoracic Society.

[13]  G. Baumann,et al.  Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. , 2006, The American journal of cardiology.

[14]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[15]  M. Gatzoulis,et al.  Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study , 2006, Circulation.

[16]  K. Dimopoulos,et al.  Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. , 2006, European heart journal.

[17]  M. Humbert,et al.  The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study , 2006, European Respiratory Journal.

[18]  P. Poole‐Wilson,et al.  Abnormal Ventilatory Response to Exercise in Adults With Congenital Heart Disease Relates to Cyanosis and Predicts Survival , 2006, Circulation.

[19]  M. Gómez-Sánchez,et al.  Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. , 2006, Chest.

[20]  R. Barst,et al.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.

[21]  M. A. Arias,et al.  Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. , 2006, European heart journal.

[22]  Frederick W. Fraunfelder,et al.  Nonarteritic Anterior Ischemic Optic Neuropathy and Sildenafil , 2006, Archives of Ophthalmology.

[23]  R. Benza,et al.  Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.

[24]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[25]  W. Klepetko,et al.  Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.

[26]  T. Welte,et al.  Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.

[27]  A. Negassa,et al.  Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. , 2005, European heart journal.

[28]  Steven H Abman,et al.  Effects of long-term bosentan in children with pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[29]  C. Seiler,et al.  Systolic right ventricular function assessment by pulsed wave tissue Doppler imaging of the tricuspid annulus. , 2005, Swiss medical weekly.

[30]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[31]  S. Hammerschmidt,et al.  Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. , 2005, Chest.

[32]  J. Parameshwar,et al.  Bosentan in inoperable chronic thromboembolic pulmonary hypertension , 2005, Thorax.

[33]  M. Humbert,et al.  Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol , 2005, Thorax.

[34]  G. Mills,et al.  The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension , 2005, European Respiratory Journal.

[35]  A. Boobis,et al.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. , 2005, British journal of clinical pharmacology.

[36]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[37]  D. Pennell,et al.  Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. , 2005, American journal of respiratory and critical care medicine.

[38]  M. Gladwin,et al.  Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension , 2005, British journal of haematology.

[39]  M. Hirshkowitz,et al.  Positive airway pressure therapy of OSA. , 2005, Seminars in respiratory and critical care medicine.

[40]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[41]  P. Robach,et al.  Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.

[42]  M. Gatzoulis,et al.  Safety and tolerability of bosentan in adults with Eisenmenger physiology. , 2005, International journal of cardiology.

[43]  B. Madden,et al.  Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. , 2005, Vascular pharmacology.

[44]  E. Fiumana,et al.  Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells , 2005, Basic Research in Cardiology.

[45]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[46]  M. Humbert,et al.  Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[47]  M. Gladwin,et al.  Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy. , 2004 .

[48]  K. Ataga,et al.  The Relationship of Pulmonary Hypertension and Survival in Sickle Cell Disease. , 2004 .

[49]  A. Ashley-Koch,et al.  Pulmonary Hypertension in SS, SC and Sβ Thalassemia: Prevalence, Associated Clinical Syndromes, and Mortality. , 2004 .

[50]  M. Gladwin,et al.  Acute on Chronic Pulmonary Hypertension in Patients with Sickle Cell Disease. , 2004 .

[51]  J. Knowles,et al.  BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease , 2004, European Respiratory Journal.

[52]  M. Hoeper,et al.  Combination therapy for pulmonary arterial hypertension: still more questions than answers , 2004, European Respiratory Journal.

[53]  F. Van de Werf,et al.  Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. , 2004, European heart journal.

[54]  G. Maislin,et al.  Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension , 2004, Circulation.

[55]  L. Tavazzi,et al.  Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. , 2004, Italian heart journal : official journal of the Italian Federation of Cardiology.

[56]  S. Rich,et al.  Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.

[57]  D. Mccrory,et al.  Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[58]  D. Mccrory,et al.  Methodology and grading for pulmonary hypertension evidence review and guideline development. , 2004, Chest.

[59]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[60]  P. Corris,et al.  Interventional and surgical modalities of treatment for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[61]  J. Barberà,et al.  Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[62]  W. Seeger,et al.  Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[63]  R. Barst,et al.  Prostanoid therapy for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[64]  R. Barst,et al.  Endothelin receptor antagonists in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[65]  R. Naeije,et al.  End points in pulmonary arterial hypertension: the way forward , 2004, European Respiratory Journal.

[66]  I. Lang.  Chronic thromboembolic pulmonary hypertension--not so rare after all. , 2004, The New England journal of medicine.

[67]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[68]  C. Strassburg,et al.  Portopulmonary hypertension and hepatopulmonary syndrome , 2004, The Lancet.

[69]  T. Young,et al.  Risk factors for obstructive sleep apnea in adults. , 2004, JAMA.

[70]  R. Speich,et al.  Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[72]  K. Kerr,et al.  Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension , 2004, European Respiratory Journal.

[73]  E. Vichinsky.  Pulmonary hypertension in sickle cell disease. , 2004, The New England journal of medicine.

[74]  M. Gladwin,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[75]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[76]  W. Seeger,et al.  Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension , 2004, European Respiratory Journal.

[77]  A. Branzi,et al.  The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.

[78]  Ori Ben-Yehuda,et al.  Preoperative Partitioning of Pulmonary Vascular Resistance Correlates With Early Outcome After Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension , 2004, Circulation.

[79]  H. Kauczor,et al.  Pulmonary hypertension in patients with chronic pulmonary thromboembolism: chest radiograph and CT evaluation before and after surgery , 2004, European Radiology.

[80]  H. Kauczor,et al.  Assessment of pulmonary hypertension by CT and MR imaging , 2004, European Radiology.

[81]  C. Silversides,et al.  Pulmonary thrombosis in adults with Eisenmenger syndrome. , 2003, Journal of the American College of Cardiology.

[82]  Carlton Dampier,et al.  Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology , 2003, The Lancet.

[83]  G. Simonneau,et al.  [Pulmonary hypertension: CT findings in pulmonary veno-occlusive disease]. , 2003, Journal de radiologie.

[84]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[85]  S. Archer,et al.  Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension , 2003, Circulation.

[86]  Arvind K. Shah,et al.  Causes of death in sickle cell disease: an autopsy study , 2003, British journal of haematology.

[87]  M. Mcgoon,et al.  Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. , 2003, Mayo Clinic proceedings.

[88]  Birgit Hay,et al.  Prevalence of symptoms and risk of sleep apnea in primary care. , 2003, Chest.

[89]  K. Brown,et al.  Expression of human herpesvirus 8 in primary pulmonary hypertension. , 2003, The New England journal of medicine.

[90]  B. Eberle,et al.  Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. , 2003, The Annals of thoracic surgery.

[91]  V. McLaughlin,et al.  Successful management of pregnancy in a patient with eisenmenger syndrome with epoprostenol. , 2003, Chest.

[92]  A. Torbicki,et al.  Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.

[93]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[94]  E. Hart,et al.  Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. , 2003, The American journal of cardiology.

[95]  W. Seeger,et al.  Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[96]  M. Gladwin,et al.  Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. , 2003, American journal of respiratory and critical care medicine.

[97]  E. Vichinsky,et al.  Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? , 2003, American journal of respiratory and critical care medicine.

[98]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[99]  A. Branzi,et al.  Women and pulmonary arterial hypertension , 2003 .

[100]  A. Parkhomenko,et al.  Management of grown up congenital heart disease. , 2003, European heart journal.

[101]  Ian Wilcox,et al.  Obstructive sleep apnea and cardiovascular disease. , 2005, Chest.

[102]  H. Okumura,et al.  Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. , 2003, Chest.

[103]  A. Torbicki,et al.  Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[104]  W. Seeger,et al.  Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[105]  C. Pegelow,et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.

[106]  R. Barst,et al.  Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.

[107]  G. Funk,et al.  Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.

[108]  J. E. Hansen,et al.  Pulmonary function in primary pulmonary hypertension. , 2003, Journal of the American College of Cardiology.

[109]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[110]  P. Arbogast,et al.  Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. , 2003, American journal of respiratory and critical care medicine.

[111]  R. Budhiraja,et al.  Portopulmonary hypertension: a tale of two circulations. , 2003, Chest.

[112]  M. Ando,et al.  Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. , 2003, Chest.

[113]  A. Cohen-Solal,et al.  Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study , 2003, Hepatology.

[114]  A. Wade,et al.  Nocturnal oxygen saturation and painful sickle cell crises in children. , 2003, Blood.

[115]  M. Humbert,et al.  An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thrombo‐embolic Pulmonary Hypertension and Lung–Heart Transplantation , 2003, Hemoglobin.

[116]  T. Flohr,et al.  Multislice CT angiography , 2001, European Radiology.

[117]  A. Branzi,et al.  Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[118]  K. Wasserman,et al.  Exercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for High Risk of Early Death , 2002, Circulation.

[119]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. , 2002 .

[120]  D. Badesch,et al.  Pulmonary hypertension associated with connective tissue disease. , 2002, Progress in cardiovascular diseases.

[121]  A. Branzi,et al.  The new clinical trials on pharmacological treatment in pulmonary arterial hypertension , 2002, European Respiratory Journal.

[122]  P. Adegboyega,et al.  Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. , 2002, Human pathology.

[123]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[124]  R. Barst,et al.  Eisenmenger's syndrome: current management. , 2002, Progress in cardiovascular diseases.

[125]  I. Khan,et al.  Acute Coronary Syndrome in Patients with Human Immunodeficiency Virus Disease , 2002, Angiology.

[126]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[127]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[128]  R. Hetzer,et al.  Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.

[129]  S. Rich,et al.  Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.

[130]  S. Archer,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .

[131]  G. Simonneau,et al.  New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[132]  W. Seeger,et al.  Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. , 2002, American heart journal.

[133]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[134]  R. Barst,et al.  Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension , 2002 .

[135]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[136]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[137]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[138]  S. Kothari,et al.  Graded balloon atrial septostomy in severe pulmonary hypertension. , 2002, Indian heart journal.

[139]  L. Rubin,et al.  Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.

[140]  M. Gladwin,et al.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[141]  R. Speich,et al.  Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.

[142]  M. Hughson,et al.  Pulmonary thrombotic arteriopathy in patients with sickle cell disease. , 2001, Archives of pathology & laboratory medicine.

[143]  J. Sandoval,et al.  Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. , 2001, American journal of respiratory and critical care medicine.

[144]  R. Ewert,et al.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[145]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[146]  D. Levy,et al.  Echocardiographic features of the right heart in sleep-disordered breathing: the Framingham Heart Study. , 2001, American journal of respiratory and critical care medicine.

[147]  G. Sybrecht,et al.  Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[148]  J. Sandoval,et al.  Atrial septostomy for pulmonary hypertension. , 2001, Clinics in chest medicine.

[149]  R. Naeije,et al.  Medical therapy of pulmonary hypertension. Conventional therapies. , 2001, Clinics in chest medicine.

[150]  A. Arroliga,et al.  Nocturnal hypoxemia is common in primary pulmonary hypertension. , 2001, Chest.

[151]  A. Chaouat,et al.  The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. , 2001, Chest.

[152]  J. E. Hansen,et al.  Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[153]  R. Chou,et al.  Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency , 2001, American journal of hematology.

[154]  M. Katayama,et al.  [Pulmonary hypertension in patients with connective tissue diseases]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[155]  M. Yigla,et al.  Primary pulmonary hypertension in Israel: a national survey. , 2001, Chest.

[156]  Jürg Reichen,et al.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.

[157]  M. Rubenfire,et al.  Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. , 2001, The European respiratory journal.

[158]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[159]  M. Rubenfire,et al.  Balloon atrial septostomy in end‐stage pulmonary hypertension guided by a novel intracardiac echocardiographic transducer , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[160]  K. Wrabec,et al.  Prognostic factors in medically treated patients with chronic pulmonary embolism. , 2001, Chest.

[161]  M. Uematsu,et al.  Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.

[162]  D. Badesch,et al.  Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[163]  M. Gatzoulis,et al.  Sildenafil in primary pulmonary hypertension. , 2000, The New England journal of medicine.

[164]  C. L. Bailey,et al.  "High probability" perfusion lung scans in pulmonary venoocclusive disease. , 2000, American journal of respiratory and critical care medicine.

[165]  H. Farber,et al.  Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.

[166]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[167]  T. W. van der Mark,et al.  Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. , 2000, The European respiratory journal.

[168]  W. Kim,et al.  Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[169]  M. Hoeper,et al.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.

[170]  J. Thumboo,et al.  Primary and secondary pulmonary hypertension in systemic lupus erythematosus , 2000, Lupus.

[171]  W. Shim,et al.  The Use of High-Resolution Computed Tomography in the Evaluation of Pulmonary Hemodynamics in Patients with Congenital Heart Disease: In Pulmonary Vessels Larger Than 1 mm in Diameter , 2000, Pediatric Cardiology.

[172]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[173]  K. Kerr,et al.  The natural history of acute and chronic thromboembolic disease: the search for the missing link. , 2000, The European respiratory journal.

[174]  A. Peacock,et al.  Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. , 2000, The European respiratory journal.

[175]  L. Hillis,et al.  Congenital heart disease in adults : Second of two parts , 2000 .

[176]  C. Sirlin,et al.  Predictors of patient response to pulmonary thromboendarterectomy. , 2000, AJR. American journal of roentgenology.

[177]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[178]  W. Seeger,et al.  A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.

[179]  J. Loyd,et al.  Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. , 2000, Chest.

[180]  C. Bergin,et al.  Identifying the cause of unilateral hypoperfusion in patients suspected to have chronic pulmonary thromboembolism: diagnostic accuracy of helical CT and conventional angiography. , 1999, Radiology.

[181]  L. Rubin,et al.  Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. , 1999, Chest.

[182]  C. Ng,et al.  A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. , 1999, Journal of thoracic imaging.

[183]  M. Sklansky,et al.  Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. , 1999, The American journal of cardiology.

[184]  J. Findlay,et al.  Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[185]  G. Koch,et al.  Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. , 1999, The American journal of cardiology.

[186]  K. Kerr,et al.  Long-term outcome after pulmonary thromboendarterectomy. , 1999, American journal of respiratory and critical care medicine.

[187]  M. Uematsu,et al.  Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[188]  P. Lange,et al.  Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects , 1999, Heart.

[189]  B. Groves,et al.  Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. , 1999, Circulation.

[190]  S. Rich,et al.  Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.

[191]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[192]  R. Whyte,et al.  Heart-lung transplantation for primary pulmonary hypertension. , 1999, The Annals of thoracic surgery.

[193]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[194]  D. Hansell,et al.  Pericardial thickening or effusion in patients with pulmonary artery hypertension: a CT study. , 1999, AJR. American journal of roentgenology.

[195]  M. Rubenfire,et al.  Echocardiographic features of primary pulmonary hypertension. , 1998, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[196]  Yue-ying Gu,et al.  Pulmonary hypertension in systemic lupus erythematosus , 1999, Rheumatology International.

[197]  P. Presbitero,et al.  Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.

[198]  S. Rybalkin,et al.  Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[199]  J. Orens,et al.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.

[200]  M. Telfer,et al.  Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. , 1998, Blood.

[201]  J. Somerville,et al.  Small ventricular septal defects in adults. , 1998, European heart journal.

[202]  S. Rich,et al.  The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. , 1998, Chest.

[203]  L. Sharples,et al.  Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[204]  Scott T. Miller,et al.  Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. , 1998, The New England journal of medicine.

[205]  J. W. Miller,et al.  Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.

[206]  M. Sugimachi,et al.  Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. , 1998, Journal of the American College of Cardiology.

[207]  L. Hillis,et al.  The Eisenmenger Syndrome in Adults , 1998, Annals of Internal Medicine.

[208]  M. Humbert,et al.  Pulmonary vascular disorders in portal hypertension. , 1998, The European respiratory journal.

[209]  J B Seward,et al.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.

[210]  R. Kuzo,et al.  Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. , 1998, Chest.

[211]  K. Kerr,et al.  Successful pulmonary thromboendarterectomy in two patients with sickle cell disease. , 1998, American journal of respiratory and critical care medicine.

[212]  W R Clarke,et al.  Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. , 1998, American journal of respiratory and critical care medicine.

[213]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[214]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[215]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[216]  F. Martinez,et al.  Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. , 1997, AJR. American journal of roentgenology.

[217]  C. Sirlin,et al.  Chronic thromboembolism: diagnosis with helical CT and MR imaging with angiographic and surgical correlation. , 1997, Radiology.

[218]  G. Klintmalm,et al.  Severe pulmonary hypertension in liver transplant candidates. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[219]  H P Gurtner,et al.  The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. , 1997, Chest.

[220]  B. Brundage,et al.  Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.

[221]  K. Maruyama,et al.  Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. , 1997, Circulation.

[222]  C. Bergin,et al.  Accuracy of MR angiography compared with radionuclide scanning in identifying the cause of pulmonary arterial hypertension. , 1997, AJR. American journal of roentgenology.

[223]  Y. Okano,et al.  Shortening of Doppler-derived deceleration time of early diastolic transmitral flow in the presence of pulmonary hypertension through ventricular interaction. , 1997, The American journal of cardiology.

[224]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[225]  G. Koch,et al.  Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension , 1997 .

[226]  R. Speich,et al.  HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.

[227]  C. Howell,et al.  Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.

[228]  G. Mengozzi,et al.  Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. , 1997, Journal of hepatology.

[229]  S. Rich,et al.  Predictors of mortality in pulmonary thromboendarterectomy. , 1996, The Annals of thoracic surgery.

[230]  J. Seward,et al.  Frequency of Doppler measurable pulmonary artery pressures. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[231]  L. Grande,et al.  Moderate Primary Pulmonary Hypertension in Patients Undergoing Liver Transplantation , 1996, Anesthesia and analgesia.

[232]  N. Ammash,et al.  Cerebrovascular events in adult patients with cyanotic congenital heart disease. , 1996, Journal of the American College of Cardiology.

[233]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[234]  L. Olson,et al.  Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. , 1996, Chest.

[235]  W. Auger,et al.  Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. , 1996, AJR. American journal of roentgenology.

[236]  R. Wiesner,et al.  Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. , 1996, Mayo Clinic proceedings.

[237]  Boxt Lm.  MR imaging of pulmonary hypertension and right ventricular dysfunction. , 1996 .

[238]  A. Chaouat,et al.  Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. , 1996, The European respiratory journal.

[239]  B. Groves,et al.  Pulmonary hypertension in chronic liver disease. , 1996, Clinics in chest medicine.

[240]  L. Sharples,et al.  Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation--early risk factors. , 1996, Transplantation.

[241]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[242]  E. Trulock,et al.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[243]  K. Kerr,et al.  Chronic thromboembolic pulmonary hypertension. , 2004, Clinics in chest medicine.

[244]  J. Russell,et al.  The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[245]  C. Benjamin,et al.  Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.

[246]  D. Stewart,et al.  Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. , 1995, Circulation.

[247]  R. Sanson-Fisher,et al.  Breaking bad news: consensus guidelines for medical practitioners. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[248]  Scott T. Miller,et al.  Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. , 1995, The Journal of pediatrics.

[249]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[250]  W. Gersony,et al.  Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. , 1995, Circulation.

[251]  A. Branzi,et al.  Role of pharmacologic tests in the treatment of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[252]  C. Bose,et al.  Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. , 1995, Biology of the neonate.

[253]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease. , 1994, The American journal of cardiology.

[254]  G. Ford,et al.  The management of pulmonary hypertension secondary to chronic thromboembolic disease. , 1994, Progress in cardiovascular diseases.

[255]  A. Alavi,et al.  Ventilation-perfusion lung scanning in the evaluation of pulmonary hypertension. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[256]  L Axel,et al.  MR imaging with spatial modulation of magnetization in the evaluation of chronic central pulmonary thromboemboli. , 1994, Radiology.

[257]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[258]  D. Sajkov,et al.  Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. , 1994, American journal of respiratory and critical care medicine.

[259]  K. Żmudka,et al.  Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. , 1994, Wiener klinische Wochenschrift.

[260]  R. Trifiletti,et al.  Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.

[261]  M. Wolf,et al.  Decreased protein S activity in sickle cell disease. , 1993, Nouvelle revue francaise d'hematologie.

[262]  P. Macchiarini,et al.  Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. , 1993, The Journal of thoracic and cardiovascular surgery.

[263]  T. Evans,et al.  L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. , 1993, British journal of clinical pharmacology.

[264]  S. Globits,et al.  Detection and quantification of pulmonary artery hypertension with MR imaging: results in 23 patients. , 1993, AJR. American journal of roentgenology.

[265]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[266]  J. Coligan,et al.  Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.

[267]  S. Rich,et al.  Successful management of labor and delivery in primary pulmonary hypertension. , 1993, The American journal of cardiology.

[268]  P. Southorn,et al.  Successful liver transplantation in patients with mild to moderate pulmonary hypertension. , 1993, Transplantation proceedings.

[269]  T. McMahon,et al.  Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. , 1993, Journal of applied physiology.

[270]  R. R. Wolfe,et al.  Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. , 1993, Circulation.

[271]  F. Fanfulla,et al.  Respiratory function in precapillary pulmonary hypertension. , 1993, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[272]  G. Gray,et al.  In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. , 1993, Journal of cardiovascular pharmacology.

[273]  S. Soifer,et al.  M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. , 1993, The American journal of physiology.

[274]  M. El-Hazmi,et al.  Blood proteins C and S in sickle cell disease. , 1993, Acta haematologica.

[275]  S. Shinohara,et al.  Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. , 1992, Japanese circulation journal.

[276]  M. O'Laughlin,et al.  Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. , 1991, Catheterization and cardiovascular diagnosis.

[277]  S. Rich,et al.  High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. , 1991, Journal of the American College of Cardiology.

[278]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[279]  A. Hadengue,et al.  Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. , 1991, Gastroenterology.

[280]  W. Auger,et al.  Chronic major-vessel thromboembolic pulmonary hypertension. , 1990, Circulation.

[281]  J. Beavo,et al.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. , 1990, Trends in pharmacological sciences.

[282]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[283]  P. Nicod,et al.  Primary pulmonary hypertension. The risk and benefit of lung biopsy. , 1989, Circulation.

[284]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[285]  K. Moser,et al.  Perfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. , 1988, Chest.

[286]  K. Peterson,et al.  Pulmonary angiography in severe chronic pulmonary hypertension. , 1987, Annals of internal medicine.

[287]  N. Kanemoto.  Natural history of pulmonary hemodynamics in primary pulmonary hypertension. , 1987, American heart journal.

[288]  Y. Hosoda,et al.  Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. , 1987, The Journal of rheumatology.

[289]  B. Brundage,et al.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.

[290]  D J Hagler,et al.  Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. , 1987, Journal of the American College of Cardiology.

[291]  B. Brundage,et al.  Antinuclear antibodies in primary pulmonary hypertension. , 1986, Journal of the American College of Cardiology.

[292]  B. Brundage,et al.  Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. , 1986, Annals of internal medicine.

[293]  C. Oakley,et al.  Factors that influence the outcome of primary pulmonary hypertension. , 1986, British heart journal.

[294]  Asherson Ra,et al.  Pulmonary hypertension and systemic lupus erythematosus. , 1986 .

[295]  M. Isobe,et al.  Prediction of pulmonary arterial pressure in adults by pulsed Doppler echocardiography. , 1986, The American journal of cardiology.

[296]  H. Moldofsky,et al.  Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. , 2015, The American review of respiratory disease.

[297]  J. Seward,et al.  Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. , 1985, Journal of the American College of Cardiology.

[298]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[299]  S. Rich,et al.  Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. , 1985, The American journal of cardiology.

[300]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[301]  P. Yock,et al.  Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. , 1984, Circulation.

[302]  M. Koss,et al.  Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. , 1984, Seminars in arthritis and rheumatism.

[303]  J. S. Bower,et al.  Differentiation of patients with primary and thromboembolic pulmonary hypertension. , 1984, Chest.

[304]  G Gamsu,et al.  CT-determined pulmonary artery diameters in predicting pulmonary hypertension. , 1984, Investigative radiology.

[305]  G. Hutchins,et al.  Primary pulmonary hypertension and cirrhosis: are they related? , 2015, The American review of respiratory disease.

[306]  D. Nelson,et al.  Peripartum Heart Failure Due to Primary Pulmonary Hypertension , 1983, Obstetrics and gynecology.

[307]  M. Hori,et al.  ECHOCARDIOGRAPHV-DOPPLER Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique , 2005 .

[308]  A. Coates,et al.  The effect of digoxin on exercise capacity and exercising cardiac function in cystic fibrosis. , 1982, Chest.

[309]  J. Widimský,et al.  Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. , 1982, Chest.

[310]  A. Churg,et al.  Severe pulmonary involvement in mixed connective tissue disease. , 1981, The American review of respiratory disease.

[311]  G E Reed,et al.  Release of nucleosides from canine and human hearts as an index of prior ischemia. , 1979, The American journal of cardiology.

[312]  R. Berne,et al.  Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. , 1975, The American journal of physiology.

[313]  J. Esterly,et al.  Pulmonary changes in sickle cell disease. , 2015, The American review of respiratory disease.

[314]  Moore Gf,et al.  Embolectomy for chronic pulmonary embolism and hypertension. , 1969 .

[315]  A. Rudolph,et al.  The natural history of ventricular septal defects in infancy. , 1965, The American journal of cardiology.

[316]  K. Moser,et al.  Chronic, Massive Thrombotic Obstruction of the Pulmonary Arteries: Analysis of Four Operated Cases , 1965, Circulation.

[317]  W. Austen,et al.  EXPERIMENTAL STUDIES OF THE SURGICAL TREATMENT OF PRIMARY PULMONARY HYPERTENSION. , 1964, The Journal of thoracic and cardiovascular surgery.

[318]  E. Besterman.  ATRIAL SEPTAL DEFECT WITH PULMONARY HYPERTENSION , 1961, British heart journal.